C07C233/36

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
20220409536 · 2022-12-29 ·

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Polyamides and amidoamines derived from hydroxyalkylpolyamines: epoxy curing agents with improved properties

Polyamide and amidoamine curing agents comprising a selectively modified amine. The selectively modified amine is formed by a substitution reaction between a polyamine and an epoxide, resulting in a multifunctional amine having a hydroxyl substituent. The curing agents are used to form epoxy resins having improved properties when cured.

Polyamides and amidoamines derived from hydroxyalkylpolyamines: epoxy curing agents with improved properties

Polyamide and amidoamine curing agents comprising a selectively modified amine. The selectively modified amine is formed by a substitution reaction between a polyamine and an epoxide, resulting in a multifunctional amine having a hydroxyl substituent. The curing agents are used to form epoxy resins having improved properties when cured.

Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. ##STR00001##

Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. ##STR00001##

Synthesis and evaluation of novel amido-amine cationic gemini surfactants containing flexible and rigid spacers

The invention concerns synthesized amido-amine-based cationic gemini surfactants with flexible and rigid spacers and different hydrophobic. These gemini surfactants were prepared by modified procedure through amidation of long chain carboxylic acids using 3-(dimethylamino)-1-propylamine followed by treatment with halohydrocarbons and showed excellent thermal stability and surface properties useful for various oilfield applications such as enhanced oil recovery.

Synthesis and evaluation of novel amido-amine cationic gemini surfactants containing flexible and rigid spacers

The invention concerns synthesized amido-amine-based cationic gemini surfactants with flexible and rigid spacers and different hydrophobic. These gemini surfactants were prepared by modified procedure through amidation of long chain carboxylic acids using 3-(dimethylamino)-1-propylamine followed by treatment with halohydrocarbons and showed excellent thermal stability and surface properties useful for various oilfield applications such as enhanced oil recovery.

Preparation of cationic surfactants
11591292 · 2023-02-28 · ·

Compositions that include cationic surfactants and methods of synthesizing compositions that include cationic surfactants. The surfactants include a quaternary amine and a saturated or unsaturated alkyl chain with 4 to 28 carbons. The surfactants can be generated by reacting a fatty acid modified with an amino alkyl group and an epihalohydrin in the presence of a base. The cationic surfactants can be generated by reacting a fatty acid modified with an amino alkyl group, an epihalohydrin, and a carboxylic acid. The cationic surfactants can be generated by reacting a carboxylic acid, an epihalohydrin, and a catalyst to afford a halo-substituted alkyl ester, followed by reacting the halo-substituted alky ester with a fatty acid modified with an amino alkyl group.

Preparation of cationic surfactants
11591292 · 2023-02-28 · ·

Compositions that include cationic surfactants and methods of synthesizing compositions that include cationic surfactants. The surfactants include a quaternary amine and a saturated or unsaturated alkyl chain with 4 to 28 carbons. The surfactants can be generated by reacting a fatty acid modified with an amino alkyl group and an epihalohydrin in the presence of a base. The cationic surfactants can be generated by reacting a fatty acid modified with an amino alkyl group, an epihalohydrin, and a carboxylic acid. The cationic surfactants can be generated by reacting a carboxylic acid, an epihalohydrin, and a catalyst to afford a halo-substituted alkyl ester, followed by reacting the halo-substituted alky ester with a fatty acid modified with an amino alkyl group.

TRNA SYNTHETASE INHIBITORS
20230102879 · 2023-03-30 ·

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.